Cargando…
Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes
BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority out...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300394/ https://www.ncbi.nlm.nih.gov/pubmed/32285629 http://dx.doi.org/10.1002/cam4.3042 |
_version_ | 1783547579411202048 |
---|---|
author | Riner, Andrea N. Underwood, Patrick W. Yang, Kai Herremans, Kelly M. Cameron, Miles E. Chamala, Srikar Qiu, Peihua George, Thomas J. Permuth, Jennifer B. Merchant, Nipun B. Trevino, Jose G. |
author_facet | Riner, Andrea N. Underwood, Patrick W. Yang, Kai Herremans, Kelly M. Cameron, Miles E. Chamala, Srikar Qiu, Peihua George, Thomas J. Permuth, Jennifer B. Merchant, Nipun B. Trevino, Jose G. |
author_sort | Riner, Andrea N. |
collection | PubMed |
description | BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority outcomes are underreported. We hypothesize that outcomes among racially/ethnically diverse PDAC patients may be influenced by treatment facility. METHODS: The National Cancer Database was used to identify 170,327 patients diagnosed with PDAC between 2004 and 2015. Cox proportional‐hazard regression was used to compare survival between race/ethnic groups across facilities. RESULTS: In unadjusted models, compared to non‐Hispanic Whites (NHW), non‐Hispanic Blacks (NHB) had the worst overall survival (HR = 1.05, 95%CI: 1.03‐1.06, P < .001) and Hispanics had the best overall survival (HR = 0.92, 95%CI: 0.90‐0.94, P < .001). After controlling for socioeconomic and clinical covariates, NHB (HR = 0.95, 95%CI: 0.93‐0.96, P < .001) had better overall survival compared to NHW, and Hispanics continued to have the best comparative outcomes (HR = 0.84, 95%CI: 0.82‐0.86, P < .001). Among Hispanics, Dominicans and South/Central Americans lived the longest, at 10.25 and 9.82 months, respectively. The improved survival in Hispanics was most pronounced at ARP (HR = 0.80, 95%CI: 0.77‐0.84, P < .001) and Integrated Network Cancer Programs (HR = 0.78, 95%CI: 0.73‐0.84, P < .001). NHB had improved survival over NHW at Comprehensive Community Care Programs (HR = 0.96, 95%CI: 0.93‐0.98, P = .002) and ARP (HR = 0.96, 95%CI: 0.94‐0.98, P = .001), which was influenced by income, education, and surgical resection. CONCLUSION: Survival was improved at ARP for all populations. Hispanics had the best comparative overall survival. NHB had improved overall survival at higher volume centers, but this was dependent upon income, education, and surgical resection. |
format | Online Article Text |
id | pubmed-7300394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73003942020-06-18 Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes Riner, Andrea N. Underwood, Patrick W. Yang, Kai Herremans, Kelly M. Cameron, Miles E. Chamala, Srikar Qiu, Peihua George, Thomas J. Permuth, Jennifer B. Merchant, Nipun B. Trevino, Jose G. Cancer Med Clinical Cancer Research BACKGROUND: Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non‐White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority outcomes are underreported. We hypothesize that outcomes among racially/ethnically diverse PDAC patients may be influenced by treatment facility. METHODS: The National Cancer Database was used to identify 170,327 patients diagnosed with PDAC between 2004 and 2015. Cox proportional‐hazard regression was used to compare survival between race/ethnic groups across facilities. RESULTS: In unadjusted models, compared to non‐Hispanic Whites (NHW), non‐Hispanic Blacks (NHB) had the worst overall survival (HR = 1.05, 95%CI: 1.03‐1.06, P < .001) and Hispanics had the best overall survival (HR = 0.92, 95%CI: 0.90‐0.94, P < .001). After controlling for socioeconomic and clinical covariates, NHB (HR = 0.95, 95%CI: 0.93‐0.96, P < .001) had better overall survival compared to NHW, and Hispanics continued to have the best comparative outcomes (HR = 0.84, 95%CI: 0.82‐0.86, P < .001). Among Hispanics, Dominicans and South/Central Americans lived the longest, at 10.25 and 9.82 months, respectively. The improved survival in Hispanics was most pronounced at ARP (HR = 0.80, 95%CI: 0.77‐0.84, P < .001) and Integrated Network Cancer Programs (HR = 0.78, 95%CI: 0.73‐0.84, P < .001). NHB had improved survival over NHW at Comprehensive Community Care Programs (HR = 0.96, 95%CI: 0.93‐0.98, P = .002) and ARP (HR = 0.96, 95%CI: 0.94‐0.98, P = .001), which was influenced by income, education, and surgical resection. CONCLUSION: Survival was improved at ARP for all populations. Hispanics had the best comparative overall survival. NHB had improved overall survival at higher volume centers, but this was dependent upon income, education, and surgical resection. John Wiley and Sons Inc. 2020-04-13 /pmc/articles/PMC7300394/ /pubmed/32285629 http://dx.doi.org/10.1002/cam4.3042 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Riner, Andrea N. Underwood, Patrick W. Yang, Kai Herremans, Kelly M. Cameron, Miles E. Chamala, Srikar Qiu, Peihua George, Thomas J. Permuth, Jennifer B. Merchant, Nipun B. Trevino, Jose G. Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title | Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title_full | Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title_fullStr | Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title_full_unstemmed | Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title_short | Disparities in Pancreatic Ductal Adenocarcinoma—The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes |
title_sort | disparities in pancreatic ductal adenocarcinoma—the significance of hispanic ethnicity, subgroup analysis, and treatment facility on clinical outcomes |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300394/ https://www.ncbi.nlm.nih.gov/pubmed/32285629 http://dx.doi.org/10.1002/cam4.3042 |
work_keys_str_mv | AT rinerandrean disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT underwoodpatrickw disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT yangkai disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT herremanskellym disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT cameronmilese disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT chamalasrikar disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT qiupeihua disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT georgethomasj disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT permuthjenniferb disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT merchantnipunb disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes AT trevinojoseg disparitiesinpancreaticductaladenocarcinomathesignificanceofhispanicethnicitysubgroupanalysisandtreatmentfacilityonclinicaloutcomes |